Thus, by inhibiting Tregs and promoting conventional T cells, human IL-18 may have potential to restore immunocompetence in cancer patients, and thereby augment the effects of cytotoxic and biologic therapies, in order to provoke and maintain an effective anti-tumor immune response. This evidence concerns the gene IL18 and neoplasm.